ArticleScientific reports2025
Natural history and prognostic nomogram of untreated triple negative breast cancer based on SEER database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review.International journal of nanomedicine · 2026Pooled it
- Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer.bioRxiv : the preprint server for biology · 2026Article
- FAK and Pyk2: Paralogous Kinases with Opposing Roles in Vasculogenic Mimicry in Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- Mechanotransduction-Induced Gene Expression Reveals Activation of TGFβ/SKIL/TAZ Axis and Supports Invasive Phenotype in Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with a relatively poor prognosis, and its natural history without therapeutic intervention remains understudied. The purpose of this study was to investigate the natural history of untreated TNBC and construct a prognostic model utilizing data from the SEER database. Data from patients diagnosed with TNBC between 2010 and 2021 were analyzed. Median survival times for each tumor stage were calculated to estimate disease progression time (defined as the difference in median survival between consecutive stages). Cox regression was employed to identify independent prognostic factors in a training set, and a prognostic nomogram was developed based on these factors. Results showed that median survival times for untreated TNBC were 65 months (stage I), 28 months (stage II), 11 months (stage III), and 3 months (stage IV), with estimated progression times from stage I to II, II to III, and III to IV being 37 months, 17 months, and 8 months, respectively. Age, multifocal breast cancer, T stage, M stage, liver metastasis, and brain metastasis were identified as independent risk factors. The nomogram demonstrated excellent predictive performance, with a C-index of 0.795 in the training set and 0.759 in the validation set, supported by favorable calibration plots and decision curve analysis (DCA). In conclusion, untreated TNBC exhibited accelerated progression and deteriorating prognosis with increasing tumor stage, with age and tumor burden serving as key prognostic indicators, and the constructed nomogram provided a reliable tool for predicting survival in untreated TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.